ReviewVirulence2025
Pathogenicity and virulence of lumpy skin disease virus: A comprehensive update.
Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- A new era in LSD control: Replacing goatpox vaccines with DIVA-enabled homologous strategies in India.Virulence · 2026Article
- Tick-borne viruses: discovery, clinical aspects, influencing factors and control.Nature reviews. Microbiology · 2026Review
- Uttarkashi-strain based goatpox vaccine provides inadequate protection against lumpy skin disease in cattle.Veterinary research communications · 2026Article
- Lumpy Skin Disease Virus Infected Calves Showing Multisystemic Vasculitis on Postmortem Examination: A Summary of Six Cases.Transboundary and emerging diseases · 2026Article
- Research Review on Inhibitors of Lumpy Skin Disease Virus: From Biological Characteristics, Drug Repurposing, to Computer-Aided Drug Design.International journal of microbiology · 2026Review
- Lumpy skin disease virus protein LSDV122 impairs IFN-I receptor complex formation to evade host innate immunity.PLoS pathogens · 2026Article
- Development of a monoclonal antibody-based competitive ELISA for serological detection of lumpy skin disease virus.Frontiers in veterinary science · 2026Article
- Spatial epidemiology of lumpy skin disease outbreaks in Thailand: proximity patterns, case concentrations, spatio-temporal clusters, and interpolated case distribution.Frontiers in veterinary science · 2026Article
- MaxEnt-based suitable areas analysis of global lumpy skin disease under current and future climate scenarios.Frontiers in microbiology · 2026Article
- Humoral and cytokine responses to a heterologous goatpox vaccine in Mithun (Frontiers in immunology · 2026Article
- Lumpy Skin Disease Virus Pathogenesis: Viral Protein Functions and Comparative Insights from Vaccinia Virus.Animals : an open access journal from MDPI · 2025Review
- Spatial Risk Distribution of Lumpy Skin Disease in Thailand Based on Maximum-Entropy Modeling.Animals : an open access journal from MDPI · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy skin disease (LSD), which was confined to the Africa for many decades, has expanded its geographical distribution to numerous countries across Asia and Europe in recent years. The LSD virus (LSDV) is a relatively poorly studied virus. Its 151 Kb genome encodes 156 open reading frames (ORF); however, the exact number of the proteins encoded by the viral genome and their specific functions remain largely unknown. Arthropod vectors primarily transmit the LSDV mechanically, but the precise nature of these vectors in different regions and their role in transmission is not fully understood. Homologous live-attenuated vaccines prepared using LSDV have proven to be highly efficacious compared to heterologous vaccines based on sheep pox virus or goatpox virus, in protecting cattle against LSD. This review offers the latest insights into the molecular biology and transmission of LSDV and discusses the safety and efficacy of available vaccines, along with the challenges faced in controlling and eradicating the disease in endemic regions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.